文献速递特殊人群用药治疗药物监测与药物基因组学

虚拟双胞胎PBPK模型支持老年患者丙戊酸精准给药

Virtual Twin Approach Using Physiologically Based Pharmacokinetic Modeling to Support Precision Dosing of Valproic Acid in Geriatric Patients.
PubMed 文献 · Clin Pharmacol Ther · 2026-06-07

本研究在74例老年患者中评估基于生理药代动力学(PBPK)的虚拟双胞胎框架前瞻性预测丙戊酸(VPA)个体暴露的能力。模型预测PK参数为观测值的0.73至1.37倍,纳入人口学与生理协变量后绝对平均折叠误差为1.13(90% CI: 1.10-1.16),近90%预测值落在观测浓度0.8至1.25倍范围内。提示PBPK引导的虚拟双胞胎可利用常规临床数据预测个体VPA暴露,补充传统治疗药物监测(TDM)以推进老年精准用药。

要点

  • PBPK虚拟双胞胎可基于常规临床数据预测老年患者VPA个体暴露。
  • 模型预测PK参数为观测值的0.73至1.37倍,验证性能可接受。
  • 近90%个体浓度预测落在观测值0.8至1.25倍范围内。

核心结论

  • PBPK引导的虚拟双胞胎能利用常规临床数据预测老年患者VPA个体暴露,可能实现前瞻性剂量优化并补充传统TDM。

研究设计与样本

  • 采用Simcyp Simulator(版本25)构建缓释VPA的PBPK模型,并基于Samsung Medical Center 74例接受VPA的老年患者临床数据生成虚拟双胞胎。
  • 模型性能先后用已发表健康成人PK数据和老年患者独立TDM数据进行验证。

主要发现

  • 模型充分再现VPA observed PK,预测PK参数为观测值的0.73至1.37倍。
  • 纳入患者人口学特征和常规可获取生理参数后,绝对平均折叠误差为1.13(90% CI: 1.10-1.16)。
  • 近90%的个体浓度预测落在观测浓度0.8至1.25倍范围内。

关键数值与推荐

  • 模型预测PK参数范围为观测值的0.73至1.37倍。
  • 个体浓度预测的绝对平均折叠误差为1.13(90% CI: 1.10-1.16)。
  • 近90%预测值落在观测浓度的0.8至1.25倍范围内。

临床怎么用

  • 对老年双相障碍患者使用VPA时,可基于人口学与常规生理参数构建虚拟双胞胎前瞻性预测个体暴露。
  • PBPK虚拟双胞胎可作为传统TDM的补充,在达稳态前辅助个体化剂量选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Personalized dosing is particularly important for drugs with narrow therapeutic indices in geriatric patients, who exhibit substantial physiological variability and limited pharmacokinetic (PK) evidence to guide individualized dose selection. Valproic acid (VPA) is an effective treatment option for bipolar disorder in older adults, yet dosing largely relies on therapeutic drug monitoring (TDM), which guides adjustment only after steady state is achieved. This study evaluated a physiologically based pharmacokinetic (PBPK)-guided virtual twin (VT) framework to prospectively predict individual VPA exposure in a real-world geriatric population. A PBPK model for extended-release VPA was developed using the Simcyp Simulator (version 25). Clinical data (n = 74) were collected from elderly patients receiving VPA at the Samsung Medical Center. PBPK model performance was validated against published PK data from healthy adults and independent TDM data from the geriatric patients. The model adequately reproduced observed PK of VPA, with predicted PK parameters ranging from 0.73- to 1.37-fold of observed values. Virtual twins were subsequently generated for each patient by incorporating patient-specific demographic characteristics and routinely available physiological parameters. Individual PK profiles were simulated and compared with measured TDM concentrations. Incorporation of demographic and physiological covariates achieved an absolute average fold error of 1.13 (90% CI: 1.10-1.16), with nearly 90% of predictions falling within the 0.8- to 1.25-fold range of the observed concentrations. These findings suggest that PBPK-guided virtual twins can predict individual VPA exposure using routinely available clinical data and may enable prospective dose optimization, complementing conventional TDM to advance precision dosing in geriatric pharmacotherapy.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jang YJ, Heo DG, Hong E, et al. Virtual Twin Approach Using Physiologically Based Pharmacokinetic Modeling to Support Precision Dosing of Valproic Acid in Geriatric Patients. Clin Pharmacol Ther. 2026. PMID: 42252689. doi:10.1002/cpt.70345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。